{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:03:19Z","timestamp":1792206199510,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"German Federal Ministry of Education and Research","award":["13N12530"],"award-info":[{"award-number":["13N12530"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ejpb.2017.04.032","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T17:15:58Z","timestamp":1493745358000},"page":"363-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"special_numbering":"C","title":["Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections"],"prefix":"10.1016","volume":"117","author":[{"given":"Nazende","family":"G\u00fcnday T\u00fcreli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afra","family":"Torge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Juntke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca C.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Schneider-Daum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akif Emre","family":"T\u00fcreli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus-Michael","family":"Lehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.ejpb.2017.04.032_b0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jcf.2005.05.005","article-title":"Infection and inflammation in cystic fibrosis: a short review","volume":"4","author":"Heijerman","year":"2005","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejpb.2017.04.032_b0010","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-9-32","article-title":"Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis","volume":"9","author":"Hoiby","year":"2011","journal-title":"BMC Med."},{"key":"10.1016\/j.ejpb.2017.04.032_b0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/49.2.235","article-title":"New antimicrobials in the management of cystic fibrosis","volume":"49","author":"Hoiby","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2017.04.032_b0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1569-1993(02)00104-2","article-title":"Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies","volume":"1","author":"Hoiby","year":"2002","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejpb.2017.04.032_b0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcf.2004.03.008","article-title":"Early intervention and prevention of lung disease in cystic fibrosis: a European consensus","volume":"3","author":"D\u00f6ring","year":"2004","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejpb.2017.04.032_b0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jcf.2009.04.005","article-title":"Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus","volume":"8","author":"Heijerman","year":"2009","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejpb.2017.04.032_b0035","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1569-1993(02)00104-2","article-title":"Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies","volume":"1","author":"Hoiby","year":"2002","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejpb.2017.04.032_b0040","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMcibr021776","article-title":"Biofilms, Antimicrobial Resistance and Airway Infections","volume":"347","author":"Prince","year":"2002","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejpb.2017.04.032_b0045","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.addr.2005.04.007","article-title":"Biofilms and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems?","volume":"57","author":"Smith","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2017.04.032_b0050","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.biomaterials.2008.12.076","article-title":"The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles","volume":"30","author":"Suk","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2017.04.032_b0055","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.284.5418.1318","article-title":"Bacterial biofilms: a common cause of persistent infections science","volume":"284","author":"Costerton","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2017.04.032_b0060","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1021\/js950381s","article-title":"Drug diffusion through cystic fibrotic mucus: steady-state permeation, rheologic properties, and glycoprotein morphology","volume":"85","author":"Bhat","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2017.04.032_b0065","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0022-3476(86)80755-7","article-title":"Antibiotic activity in sputum","volume":"108","author":"Levy","year":"1986","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ejpb.2017.04.032_b0070","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.addr.2007.11.006","article-title":"Targeted delivery of nanoparticles for the treatment of lung diseases","volume":"60","author":"Azarmi","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2017.04.032_b0075","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijpharm.2008.02.011","article-title":"Inhaled nanoparticles\u2013a current review","volume":"356","author":"Yang","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.04.032_b0080","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2174\/092986710790416290","article-title":"Development of nanoparticles for antimicrobial drug delivery","volume":"17","author":"Zhang","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejpb.2017.04.032_b0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2014.06.055","article-title":"Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors","volume":"192C","author":"Nafee","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2017.04.032_b0090","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jconrel.2014.03.055","article-title":"Lipid and polymer nanoparticles for drug delivery to bacterial biofilms","volume":"190C","author":"Forier","year":"2014","journal-title":"J. Control. Release"},{"issue":"suppl 1","key":"10.1016\/j.ejpb.2017.04.032_b0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/08958370902962283","article-title":"Inhalative nanomedicine\u2013opportunities and challenges","volume":"21","author":"Bur","year":"2009","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.ejpb.2017.04.032_b0100","doi-asserted-by":"crossref","first-page":"19268","DOI":"10.1073\/pnas.0905998106","article-title":"Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier","volume":"106","author":"Tang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2017.04.032_b0105","doi-asserted-by":"crossref","DOI":"10.1007\/s13346-011-0048-9","article-title":"Biodegradable mucus-penetrating nanoparticles composed of diblock copolymers of polyethylene glycol and poly(lactic\u2013glycolic acid)","volume":"2","author":"Yu","year":"2012","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2017.04.032_b0110","article-title":"Inhalable antibiotic nanoformulations for the treatment of pseudomonas aeruginosa infection in cystic fibrosis \u2013 a review","volume":"4","author":"G\u00fcnday T\u00fcreli","year":"2014","journal-title":"Drug Deliv. Lett."},{"key":"10.1016\/j.ejpb.2017.04.032_b0115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ijpharm.2003.09.041","article-title":"Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to lung","volume":"269","author":"Sham","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.04.032_b0120","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.addr.2010.11.002","article-title":"Formation, characterization and fate of inhaled drug nanoparticles","volume":"63","author":"Zhang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2017.04.032_b0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1166\/jbn.2007.015","article-title":"Nanoparticles: characteristics, mechanisms of action, and toxicity in pulmonary drug delivery \u2013 a review","volume":"3","author":"Gill","year":"2007","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2017.04.032_b0130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijpharm.2016.10.025","article-title":"Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: design of experiments approach","volume":"515","author":"T\u00fcreli","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.04.032_b0135","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S1526-0550(02)00003-3","article-title":"Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence","volume":"3","author":"Davies","year":"2002","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.ejpb.2017.04.032_b0140","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0092-8674(00)81099-5","article-title":"Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid","volume":"85","author":"Smith","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.ejpb.2017.04.032_b0145","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1081\/DDC-100102197","article-title":"Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method","volume":"25","author":"Barichello","year":"1999","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2017.04.032_b0150","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2017.04.032_b0155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0168-3659(98)00116-3","article-title":"PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug","volume":"57","author":"Govender","year":"1999","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2017.04.032_b0160","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"key":"10.1016\/j.ejpb.2017.04.032_b0165","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2147\/IJN.S40579","article-title":"Concepts and practices used to develop functional PLGA-based nanoparticulate systems","volume":"8","author":"Sah","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejpb.2017.04.032_b0170","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ijpharm.2016.08.004","article-title":"Counter-ion complexes for enhanced drug loading in nanocarriers: proof-of-concept and beyond","author":"T\u00fcreli","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.04.032_b0175","unstructured":"Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard\u2014Ninth Edition, Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087\u20131898 USA, 2006."},{"key":"10.1016\/j.ejpb.2017.04.032_b0180","series-title":"Light Scattering by Particles in Water \u2013 Theoretical and Experimental Foundations","author":"Jonasz","year":"2007"},{"key":"10.1016\/j.ejpb.2017.04.032_b0185","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s11095-014-1612-z","article-title":"Semi-automated nanoprecipitation-system\u2013an option for operator independent, scalable and size adjustable nanoparticle synthesis","volume":"32","author":"Rietscher","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2017.04.032_b0190","doi-asserted-by":"crossref","first-page":"6","DOI":"10.14227\/DT170210P6","article-title":"Optimization of an in vitro dissolution test method for inhalation formulations","author":"Son","year":"2010","journal-title":"Dissolution Technol."},{"key":"10.1016\/j.ejpb.2017.04.032_b0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.14227\/DT180311P15","article-title":"Simulated biological fluids with possible application in dissolution testing","author":"Marques","year":"2011","journal-title":"Dissolution Technol."},{"key":"10.1016\/j.ejpb.2017.04.032_b0200","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejps.2017.04.003","article-title":"The influence of mannitol on morphology and disintegration of spray-dried nano-embedded microparticles","volume":"104","author":"Torge","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2017.04.032_b0205","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0168-3659(01)00248-6","article-title":"On the importance and mechanisms of burst release in matrix-controlled drug delivery systems","volume":"73","author":"Huang","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2017.04.032_b0210","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/0142-9612(95)93575-X","article-title":"Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition","volume":"16","author":"Park","year":"1995","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2017.04.032_b0215","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijpharm.2016.01.021","article-title":"Impact of PEG and PEG-b-PAGE modified PLGA on nanoparticle formation, protein loading and release","volume":"500","author":"Rietscher","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.04.032_b0220","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","article-title":"Modeling and comparison of dissolution profiles","volume":"13","author":"Costa","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2017.04.032_b0225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0168-3659(87)90034-4","article-title":"A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs","volume":"5","author":"Ritger","year":"1987","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2017.04.032_b0230","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijpharm.2010.10.037","article-title":"Elaborations on the Higuchi model for drug delivery","volume":"418","author":"Paul","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.04.032_b0235","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1166\/jnn.2014.9015","article-title":"Mucus as barrier for drug delivery by nanoparticles","volume":"14","author":"Frohlich","year":"2014","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.ejpb.2017.04.032_b0240","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2017.04.032_b0245","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1164\/ajrccm.162.5.9909009","article-title":"Cystic fibrosis sputum: a barrier to the transport of nanospheres","volume":"162","author":"Sanders","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejpb.2017.04.032_b0250","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1166\/jbn.2014.1939","article-title":"Lung toxicity of biodegradable nanoparticles","volume":"10","author":"Fattal","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2017.04.032_b0255","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jconrel.2011.08.032","article-title":"A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles","volume":"157","author":"Mert","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2017.04.032_b0260","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.biomaterials.2013.01.064","article-title":"Nanoparticle diffusion in respiratory mucus from humans without lung disease","volume":"34","author":"Schuster","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2017.04.032_b0265","unstructured":"Breakpoint tables for interpretation of MICs and zone diameters, in: The European Committee on Antimicrobial Susceptibility Testing, 2014."},{"issue":"suppl 3","key":"10.1016\/j.ejpb.2017.04.032_b0270","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1086\/321846","article-title":"Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity","volume":"33","author":"Peterson","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2017.04.032_b0275","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/jac\/43.suppl_1.43","article-title":"Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose","volume":"43","author":"Birmingham","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2017.04.032_b0280","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study","volume":"33","author":"Stass","year":"2013","journal-title":"Clin. Drug Invest."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641116309924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641116309924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T05:57:38Z","timestamp":1535867858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641116309924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":56,"alternative-id":["S0939641116309924"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2017.04.032","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2017.04.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}